Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Acupuncture

Therapeutic area intelligence for Acupuncture with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 1

Companies

pharma companies in pain management →

Assets

Acupuncture →

Recent signals(3)

ClinicalJuly 14, 2026

Trial on Thread-Embedding Acupuncture for Chronic Low Back Pain Initiated

A clinical trial is underway to assess the efficacy of thread-embedding acupuncture versus sham treatment in chronic low back pain.

ClinicalJuly 9, 2026

Acupuncture Trial for Heel Pain Syndrome Shows Promise in Pain Relief and Function

A randomized controlled trial is evaluating the efficacy of acupuncture at the Heel Pain Point for treating heel pain syndrome, comparing it to manual therapy and sham acupuncture.

ClinicalJune 26, 2026

Study on Electroacupuncture's Impact on Bowel Motility in Healthy Subjects

A clinical trial is investigating the effects of electroacupuncture at NP82 and SP15 on bowel motility in healthy subjects.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.